HNGE Company Profile and Key Details

HNGE has shown weak momentum, losing -14.13% over the past week and -15.54% over the past quarter, though year-to-date performance is down -10.4%. Short-term trend indicators are bullishly aligned (SMA20 17.41%, SMA50 3.1%, SMA200 -7.11%). The stock’s 14-day RSI is 60.61 (firm momentum), while the ATR of 2.48 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.77% below its high and over 45.18% above its low. Average 10-day trading volume of 810.95 thousand shares is below the 3-month average of 1.21 million, indicating normal recent market interest.

Hinge Health, Inc. has 27.22 million shares outstanding. The public float is 21.69 million shares, elevated short interest at 4.32% of float. This equals 1.12 million shares. The short ratio is 1.4 days. Institutional investors hold 171.0% of the float. Insiders own 22.87%. Bessemer Venture Partners X L.P. holds 3.38 million shares, Pursley James has 732.10 thousand shares and Budge James has 401.43 thousand shares. Over the past six months, insider transactions show net selling. They sold 1.20 million shares across 24 transactions.

Hinge Health, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $19.94. This means the shares are trading above this model’s fair value.

Hinge Health, Inc. (NYSE:HNGE) closed at $43.65 USD, gaining $0.33 (0.76%) from the previous close of $43.32. The stock is currently mid-range between its 52-week high and low $30.08 and $62.18. With a market capitalization of about $3.44 billion, Hinge Health, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.81). Key stats such as the average daily volume over the past year has been around 1.24 million shares, volume is running light vs its 52-week average. Headquartered in San Francisco, CA, Hinge Health, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Daniel A. Perez, the company employs approximately 1,514 people and listed since May 22, 2025. Hinge Health, Inc. develops health care software for joint and muscle health.

Wall Street analysts project EPS growth of 1.95% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 27 Strong Buy ratings, 15 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $72.00 to $41.00. The high target offers 66.2% upside. The low target suggests -5.36% downside. The mean target is $57.60. This offers 32.96% upside. Hinge Health, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 41.67%. The prior quarter beat by 644.44%. Over the last six quarters, Apple has recorded several small beats. These include 644.44% in August 05, 2025.

Hinge Health, Inc. (NYSE:HNGE) shares are down -10.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Hinge Health, Inc. trading at a premium to the broader market with a P/E of -6.52. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $57.60, suggesting 32.96% upside. Our AI forecast model points to short-term weakness (-9.58% over two weeks), a medium-term rise (26.8% over three months), and a longer-term loss (-1.85% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Hinge Health, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.58%, with price expected at $39.17 by May 01, 2026, within a range of $37.26 to $41.24 3-Month Outlook: Projected rise of 26.8%, reaching $54.93 by July 16, 2026, with a range of $53.94 to $55.84. 1-Year Outlook: Projected loss of -1.85%, with price at $42.52 by April 16, 2027, within a range of $40.41 to $44.50.

Hinge Health, Inc. trades at a P/E ratio of -6.52, slightly below the S&P 500 average, with a price-to-sales ratio of 5.8 and a price-to-book ratio of 9.1 trading at moderately above to book value. The P/FCF stands at 20.39, also above market averages.